FDA approves Indivior's Sublocade injection for opioid addiction
Indivior yesterday announced that the FDA has approved Sublocade injection for subcutaneous use, the first and only once-monthly injectable buprenorphine formulation for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product followed by dose adjustment for a minimum of seven days. Sublocade is expected to be available to patients in the U.S. in Q1 of 2018. The injection contains buprenorphine, a partial agonist at the mu-opioid receptor. Alkermes' (ALKS) Vivitrol is currently on the market as a once-monthly treatment to prevent relapse in opioid dependent patients following detoxification.